O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
Titel:
O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
Auteur:
Dore, G. Grebely, J. Altice, F. Litwin, A.H. Dalgard, O. Gane, E.J. Shibolet, O. Luetkemeyer, A. Nahass, R. Peng, C.Y. Conway, B. Iser, D.M. Huang, H.C. Gendrano, I.N. Kelly, M. Hwang, P. Robertson, M. Wahl, J. Barr, E. Platt, H.L.